Algenex
Biotechnology company that uses insect hosts and baculovirus vector expression to produce recombinant proteins at scale. Operates automated insect-pupa single-use bioreactor production and employs proprietary genetic expression cassettes to increase yield and stability. Focus areas include recombinant vaccine antigens (veterinary and human), diagnostic antigens, and non-mammalian biocomponents. Operates GMP-certified facilities in Tres Cantos (Madrid). In 2022 the company became part of a group of pharmaceutical companies led by the founders of Insud Pharma, and is progressing platform adaptation for human-health applications.
Industries
Nr. of Employees
small (1-50)
Algenex
Ronda de Poniente, 14, 28760 Tres Cantos, Madrid, Spain
Patents
Baculoviral DNA elements for the expression of recombinant proteins in a host cell
US-9982239-B2
View DetailsBaculoviral DNA elements for the expression of recombinant proteins in a host insect
US-9701983-B2
View Details
Baculoviral DNA elements for the expression of recombinant proteins in a host cell
US-9982239-B2
View DetailsBaculoviral DNA elements for the expression of recombinant proteins in a host insect
US-9701983-B2
View DetailsProducts
Veterinary recombinant subunit vaccine produced with insect-based platform (marketing authorized in EU/UK)
Veterinary recombinant subunit vaccine produced using the insect-based expression platform; received regulatory marketing authorization in the EU and UK for a rabbit haemorrhagic disease vaccine.
ASFV antibody rapid diagnostic test (partner commercialized)
Point-of-care antibody detection assay for African swine fever based on recombinant antigen produced by the insect-based platform; marketed via partner distribution channels.
Veterinary recombinant subunit vaccine produced with insect-based platform (marketing authorized in EU/UK)
Veterinary recombinant subunit vaccine produced using the insect-based expression platform; received regulatory marketing authorization in the EU and UK for a rabbit haemorrhagic disease vaccine.
ASFV antibody rapid diagnostic test (partner commercialized)
Point-of-care antibody detection assay for African swine fever based on recombinant antigen produced by the insect-based platform; marketed via partner distribution channels.
Services
Development and production services for recombinant antigens and vaccine candidates using insect-based baculovirus expression and proprietary expression cassettes; includes antigen supply for formulation and diagnostics.
Licensing of expression platform and collaborative development agreements for vaccine candidates and diagnostic reagents with commercial partners worldwide.
Production and supply of recombinant antigens for serological and rapid diagnostic kits, with capability to support validation and commercialization through partner channels.
Operational support and services for large-scale rearing of insect hosts used as production feedstock, integrated with expression workflows for continuous manufacturing.
Development and production services for recombinant antigens and vaccine candidates using insect-based baculovirus expression and proprietary expression cassettes; includes antigen supply for formulation and diagnostics.
Licensing of expression platform and collaborative development agreements for vaccine candidates and diagnostic reagents with commercial partners worldwide.
Production and supply of recombinant antigens for serological and rapid diagnostic kits, with capability to support validation and commercialization through partner channels.
Operational support and services for large-scale rearing of insect hosts used as production feedstock, integrated with expression workflows for continuous manufacturing.
Expertise Areas
- Recombinant protein production
- Vaccine antigen design and development (veterinary and human)
- Baculovirus expression vector systems
- Bioprocess scale-up and industrial manufacturing
Key Technologies
- Baculovirus expression vector systems (BEVS)
- Insect pupa/chrysalis single-use bioreactors
- Genetic expression cassette engineering
- Automated protein extraction from insect hosts
News & Updates
Company notice for general shareholders meetings.
Discussion of research into insect-pupa based production units as a method to accelerate vaccine antigen production.
Announcement of progress toward applying insect-based production technology to human vaccine development.
Award of public funding to support development of products targeting SARS-CoV-2 using the company's platform.
Announcement of marketing authorization in EU and UK for a veterinary vaccine produced with the insect-based platform following a positive regulatory opinion.
Announcement of GMP certification for manufacture of active substances for human and veterinary medicines at Tres Cantos facilities.
Company notice for general shareholders meetings.
Discussion of research into insect-pupa based production units as a method to accelerate vaccine antigen production.
Announcement of progress toward applying insect-based production technology to human vaccine development.
Award of public funding to support development of products targeting SARS-CoV-2 using the company's platform.
Announcement of marketing authorization in EU and UK for a veterinary vaccine produced with the insect-based platform following a positive regulatory opinion.
Announcement of GMP certification for manufacture of active substances for human and veterinary medicines at Tres Cantos facilities.